Source: Public company announcement Billion Market value | ' Altar ' | Fall! Hua Big gene stock price fell probably year

Medical network October 26 Last July, the big gene officially landed a a-share, the market value has broken through hundreds of billions, the stock price is second only to Maotai, is unlimited scenery;

Hundreds of billions of market value ' altars ' fall

China big Gene Performance list (unit: billion) July 14, 2017, the official listing of China big gene, a continuous plate number of up to 18, November 14, the market value of hundreds of billions of dollars, its share price once climbed 260 yuan high, second only to Maotai; July 16, 2018, 206 million of the restricted shares lifted, the opening and closing of the day, October 23 Close, the share price of 49.96 yuan, as of October 25 close, market value of 20.9 billion yuan.

For more than a year, the share price of Hua big gene ' discount ', the market value evaporated 80 billion yuan. The main business income of the Huada gene is from childbirth Health , complex diseases, basic scientific research and drug research and development four sectors, of which the top three sectors accounted for the total operating income ratio of 95%. According to the China big gene 2018 years ago, the three quarterly results show that the expected net profit of 315 million-330 million yuan, an increase of 0.82%-5.63%, the performance growth is mainly the company's business overall continuation of the first half of the growth trend, reproductive health, basic research,

Businesses such as complex diseases and drug discovery continued to grow from a year earlier. However, the growth in China's big gene appears to have failed to reverse the decline in share prices.

Be questioned about illegal practice

Recently, the Chinese big gene released a notice, noted that Sina Weibo, a person user re-release of relevant information, involving the poor dissemination of false information of listed companies, and rumors mainly questioned the existence of illegal practice of listed companies. In response, the Huada gene responded that the non-invasive prenatal genetic testing institutions have a medical institution license, and obtained a clinical gene amplification test Laboratory Technical Acceptance certificate, testing equipment, reagents and data analysis software have been food Drug The supervision and management department approves the registration, the laboratory personnel who are engaged in the examination have obtained the clinical gene amplification Examination Technical Training certificate. Hua da gene to carry out non-invasive prenatal genetic testing in line with relevant laws Regulations

' Reduction + turnover ' stock price drop stop On the evening of October 15, the shareholder of Dahua gene in Shenzhen Qianhai big gene Investment Enterprise (Limited Partnership) (hereinafter referred to as: China big Investment) plans to reduce the company's shares not more than 12.003 million shares, not exceeding the total capital of the company 3%. The current director of the company Wang June, BGI, Sun Yingjun, the current Supervisor Lisong Gang, the current executive Du, outgoing director Li Yinglui, the outgoing executive Wang Wei through China's investment indirectly holding the shares of the company.

According to data, China large investment holdings 66.9152 million shares, the shareholding ratio of 16.72%, is the second largest shareholder. October 16, the big gene issued a notice, the original term until the second session of the Board of directors expires on June 18, 2021 Wang June, for personal reasons, resigned from the position of director, resigned from the company does not hold any post.

Wang June holds 53.79% of China Investment Partnership, with a contribution of 26.856 million yuan. However, the "reduction + turnover" news caused concern for investors, Hua big Gene shares fell. October 17, the Chinese big gene in the investor interactive platform to respond that the investment is not the company's controlling shareholders, the reduction will not affect the company's governance structure and sustainable management, the proposed reduction of shareholding mainly from Wang June, Wang June through China's investment indirectly holding shares of listed companies. The move is not a reduction in the company's current executives, the earlier announcement of the 190 million increase in the implementation of the plan, the company will issue an increase in the progress announcement as soon as possible. Wang June the reduction plan and the resignation of the director is due to the need for their own capital co-ordination, and concentrate on developing their own Business

Dong Kao Jen holding nearly 200 million to reverse the downturn

Implementation of overweight July 17-23rd, Hua big gene bursts three increase notice, increase the total amount of 190 million yuan, the main body includes the company chairman, directors, executives and so on.

Among them, the company's actual controller/Chairman Wang Jian, the company director Sun Yingjun and the controlling shareholder of China large holding core management team to increase the amount of the most, cumulative not less than 150 million yuan. According to the latest Chinese gene announcement, as of October 16, the total increase of 107,600 shares, accounting for 0.0269% of the total share capital, increase the amount of 7.9417 million yuan. By the end of January 23, 2019 at the latest, this means that the remaining excess of $180 million will be completed within the next three months.

There are insiders analysis pointed out that in the current a-share collapse of the situation, the market sentiment is relatively depressed, the director of the Kao Jen holding slow progress, perhaps its share price and adjust the space. As a leading enterprise in the domestic gene testing industry, Huada gene has been attracting attention since its listing, and has adhered to its development goals even in the face of numerous doubts. Recently, Hua Big Gene said, as of June 30, 2018, the company's cancer early screening project has completed the pre-development of technology, product development continues to smooth progress.

The goal of the future is to develop the world's leading cancer screening products, providing a comprehensive solution for early screening and early detection of tumors.